VIDEO: New study highlights need for treatment options for diffuse cutaneous systemic sclerosis

A new study has suggested that with current immunosuppressive therapies, about 20% of people with early or at-risk diffuse cutaneous systemic sclerosis (dcSSc) experienced worsening of skin and lung involvement within three years.